

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following Phase III trials investigating PARP inhibitors as first-line maintenance therapy for advanced ovarian cancer enrolled patients with BRCA mutations only?  
a. SOLO-1  
b. PAOLA-1  
c. PRIMA  
d. VELIA
2. The Phase II OVARIO trial evaluated which of the following PARP inhibitors in combination with bevacizumab after first-line platinum chemotherapy/ bevacizumab for patients with advanced ovarian cancer?  
a. Olaparib  
b. Niraparib  
c. Rucaparib  
d. Veliparib
3. Which of the following is the best description of the mechanism by which tumor treating fields promote tumor cell death?  
a. Altered cell division  
b. Necrosis  
c. Detachment from matrix  
d. Autophagy
4. What is the target of the novel antibody-drug conjugate upifitamab rilsodotin, currently under investigation for ovarian cancer?  
a. Folate receptor alpha  
b. NaPi2b  
c. Tissue factor  
d. TROP2
5. Which of the following cohorts of patients with relapsed ovarian cancer in the OReO trial experienced a statistically significant progression-free survival benefit with olaparib after prior exposure to a PARP inhibitor?  
a. Patients without BRCA mutations  
b. Patients with BRCA mutations  
c. Both a and b  
d. No benefit was observed in either cohort